Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm)

Critical Reviews in Oncology/Hematology

Volumn 59, Issue 1, 2006, Pages 40-50

  de Castro Junior, Gilberto ^a   Puglisi, Fabio ^b   de Azambuja, Evandro ^a   El Saghir, Nagi S ^c   Awada, Ahmad ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Angiogenesis; Antiangiogenesis agents; Bevacizumab; Metronomic chemotherapy; Molecular target therapy; Sorafenib; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MARIMASTAT; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; OXALIPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; SORAFENIB; SUNITINIB; THALIDOMIDE; THROMBOSPONDIN 1; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; ARTERY THROMBOSIS; BLEEDING; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ERUPTION; FATIGUE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NONHUMAN; PROTEINURIA; RADIATION DOSE; REVIEW; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33745141942     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.02.007     Document Type: Review

References (94)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
3. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 (2002) 727-739
4. Fidler I.J., and Ellis L.M. Neoplastic angiogenesis-not all blood vessels are created equal. NEJM 351 (2004) 215-216
5. Jain R.K. Molecular regulation of vessel maturation. Nat Med 9 (2003) 685-693
6. Papetti M., and Herman I.M. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 285 (2002) C947-C970
7. Streubel B., Chott A., Huber D., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351 (2004) 250-259
8. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
9. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77 (1999) 527-543
10. Cross M.J., Dixelius J., Matsumoto T., and Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 28 (2003) 488-494
11. Connolly D.T. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 47 (1991) 219-223
12. Ferrara N., Houck K., Jakeman L., and Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13 (1992) 18-32
13. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 (2002) 4368-4380
14. Zeng H., Dvorak H.F., and Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 276 (2001) 26969-26979
15. De Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., and Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255 (1992) 989-991
16. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 (1999) 9-22
17. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 (2002) 795-803
18. Chang L., Kaipainen A., and Folkman J. Lymphangiogenesis new mechanisms. Ann NY Acad Sci 979 (2002) 111-119
19. He Y., Karpanen T., and Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 1654 (2004) 3-12
20. Iliopoulus O., Levy A.P., Jiang C., Kaelin Jr. W.G., and Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93 (1996) 10595-10599
21. Siemeister G., Weindel K., Mohrs K., Barleon B., Martiny-Baron G., and Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56 (1996) 2299-2301
22. Gnarra J.R., Zhou S., Merrill M.J., et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93 (1996) 10589-10594
23. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
24. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
25. Dameron K.M., Volpert O.V., tainsky M.A., and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 (1994) 1582-1584
26. Streit M., Riccardi L., Velasco P., et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96 (1999) 14888-14893
27. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostat a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung F carcinoma. Cell 79 (1994) 315-328
28. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
29. Maione T.E., Gray G.S., Petro J., et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247 (1990) 77-79
30. Singh R.K., Gutman M., Bucana C.D., Sanchez R., Llansa N., and Fidler I.J. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92 (1995) 4562-4566
31. O'Reilly M.S., Pirie-Shepherd S., Lane W.S., and Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285 (1999) 1926-1928
32. Folkman J., and Kalluri R. Tumor angiogenesis. In: Kufe D.W., Pollock R.E., Weichselbaum R.R., et al. (Eds). Cancer medicine (2003), BC Decker, London 161-194
33. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
34. Tufan A.C., and Satiroglu-Tufan N.L. The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of antiangiogenic agents. Curr Cancer Drug Targets 5 (2005) 249-266
35. Hanahan D., Christofori G., Naik P., and Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for pre-clinical therapeutic models. Eur J Cancer 32A (1996) 2386-2393
36. Bergers G., Javaherian K., Lo K.M., Folkman J., and Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 (1999) 808-812
37. Folkman J., Browder T., and Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 86 (2001) 23-33
38. Pasquier E., Honore S., Pourroy B., et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65 (2005) 2433-2440
39. Hotchkiss K.A., Ashton A.W., Mahmood R., Russell R.G., Sparano J.A., and Schwartz E.L. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel: association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 1 (2002) 1191-1200
40. Clements M.K., Jones C.B., Cumming M., and Daoud S.S. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 44 (1999) 411-416
41. Gasparini G., Longo R., Fanelli M., and Teicher B.A. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23 (2005) 1295-1311
42. Horstmann E., McCabe M.S., Grochow L., et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352 (2005) 895-904
43. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
44. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
45. Giantonio B.J., Catalano P.J., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23 16S PtI (2005) 1s
46. Kabbinavar F.F., Hambleton J., Mass R.D., Hurvitz H.I., Bergsland E., and Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005) 3706-3712
47. Fernando N., Yu D., Morse M., et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. J Clin Oncol 23 16S Pt I (2005) 260s
48. Jain R.K. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
49. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
50. Sobrero A., and Bruzzi P. Bevacizumab plus fluorouracil: the value of being part of a developing story. J Clin Oncol 23 (2005) 3660-3662
51. Sandler A.B., Gray R., Brahmer J., et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol 23 16S PtI (2005) 2s
52. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
53. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
54. Chen H.X., Mooney M., Boron M., et al. Bevacizumab plus 5-FU/leucovorin for advanced colorectal cancer that progressed after standard chemotherapies: an NCI Treatment Referral Center Trial (TRC-0301). J Clin Oncol 22 14S (2004) 248s
55. Relf M., LeJeune S., Scott P.A., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57 (1997) 963-969
56. Miller K., Wang M., Gralow J., et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100). Eur J Cancer Suppl 3 2 (2005) 77-78
57. Schneider B.P., and Miller K.D. Angiogenesis of breast cancer. J Clin Oncol 23 (2005) 1782-1790
58. Herbst R.S., Onn A., and Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23 (2005) 3243-3256
59. Spigel D.R., Hainsworth J.D., Sosman J.A., et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma: update of a phase II multicenter trial. J Clin Oncol 23 16S Pt I (2005) 387s
60. Awada A., Hendlisz A., Gil T., et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors. Br J Cancer 92 (2005) 1855-1861
61. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
62. Ratain M.J., Eisen T., Stadler W.M., et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol 23 16S Pt I (2005) 388s
63. D'Hondt V., Gil T., Lalami Y., Piccart M., and Awada A. Will the dark sky over advanced renal cell carcinoma soon become brighter?. Eur J Cancer 41 (2005) 1246-1253
64. Escudier B., Szczylik C., Eisen T., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol 23 16S Pt I (2005) 380s
65. Demetri G.D., van Oosterom A.T., Blackstein M., et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. J Clin Oncol 23 16S PtI (2005) 308s
66. Hecht J.R., Trarbach T., Jaeger E., et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK222584 or placebo (CONFIRM-1). J Clin Oncol 23 16S Pt I (2005) 2s
67. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., and Buckels J.A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87 (2002) 161-167
68. Shepherd F.A., Giaccone G., Seymour L., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20 (2002) 4434-4439
69. Bisset D., O'Byrne K.J., von Pawel J., et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23 (2005) 842-849
70. Leighl N.B., Paz-Ares L., Douillard J.Y., et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR 18. J Clin Oncol 23 (2005) 2831-2839
71. Levitt N.C., Eskens F.A., O'Byrne K.J., et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor MMI270 (CGS27023A) in patients with advanced solid cancer. Clin Cancer Res 7 (2001) 1912-1922
72. Kerbel R.S., and Kamen B.A. The antiangiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4 (2004) 423-436
73. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
74. Klement G., Huang P., Mayer B., et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8 (2002) 221-232
75. Bocci G., Francia G., Man S., Lawler J., and Kerbel R.S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100 (2003) 12917-12922
76. Bertolini F., Paul S., Mancuso P., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63 (2003) 4342-4346
77. Hamano Y., Sugimoto H., Soubasakos M.A., et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64 (2004) 1570-1574
78. Colleoni M., Rocca A., Sandri M.T., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13 (2002) 73-80
79. Kerbel R.S. A cancer therapy resistant to resistance. Nature 390 (1997) 335-336
80. Gerhardt H., and Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314 (2003) 15-23
81. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23 (2005) 939-952
82. Gasparini G., and Harris A.L. Prognostic significance of tumor vascularity. In: Teicher B.A. (Ed). Antiangiogenic agents in cancer therapy (1999), Humana Press, Totowa (NJ) 317-399
83. Hlatky L., Hahnfeldt P., and Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94 (2002) 883-893
84. Goede V., Schimidt T., Kimmina S., Kozian D., and Augustin H.G. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 78 (1998) 1385-1394
85. Kakolyris S., Fox S.B., Koukourakis M., et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component LH39. Br J Cancer 82 (2000) 844-851
86. St Croix, Rago C., Velculescu V., et al. Genes expressed in human tumor endothelium. Science 289 (2000) 1197-1202
87. Toi M., Matsumoto T., and Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2 (2001) 667-673
88. Nguyen M., Watanabe H., Budson A.E., Richie J.P., Hayes D.F., and Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86 (1994) 356-361
89. Dirix L.Y., Vermeulen P.B., Pawinski A., et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76 (1997) 238-243
90. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 (2001) 843-850
91. Gasparini G. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 37 (2001) 97-114
92. Willet C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
93. Leach M.O., Brindle K.M., Evelhoch J.L., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92 (2005) 1599-1610
94. Morgan B., Thomas A.L., Drevs J., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584 an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21 (2003) 3955-3964